Nevertheless, all patients with a mCRC harboring RAS PLLM and/or RAS mutations in a limited part of the tumor (i.e., intra- or inter-tumoral heterogeneity), and treated with anti-EGFR mAbs showed disease progression (n = 5). This evidence concerns the gene EGFR and neoplasm.